Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease

(2022) Nicholas J. Ashton et al.   EBioMedicine

Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease

(2021) Ming Lu et al.   JAMA Neurology

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease

(2021) Cécile Tissot et al.   Alzheimers Research & Therapy

Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography

(2020) Pierre-François Meyer et al.   JAMA Neurology

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   NATURE MEDICINE

18F-MK-6240 PET for early and late detection of neurofibrillary tangles

(2020) Tharick A Pascoal et al.   BRAIN

Impact of p-tau181 and p-tau217 levels on enrolment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs

(2020) Serge Gauthier et al.   Expert Review of Neurotherapeutics

Rapid Progress Toward Reliable Blood Tests for Alzheimer Disease

(2020) Elisabeth H. Thijssen et al.   JAMA Neurology

Tau PET imaging in neurodegenerative tauopathies—still a challenge

(2019) Antoine Leuzy et al.   MOLECULAR PSYCHIATRY

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

(2019) Sebastian Palmqvist et al.   EMBO Molecular Medicine

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

(2018) Michelle M. Mielke et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Apolipoprotein E, Receptors, and Modulation of Alzheimer’s Disease

(2018) Na Zhao et al.   BIOLOGICAL PSYCHIATRY

Longitudinal tau PET in ageing and Alzheimer’s disease

(2018) Clifford R Jack et al.   BRAIN

Imaging the evolution and pathophysiology of Alzheimer disease

(2018) William Jagust   NATURE REVIEWS NEUROSCIENCE

Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic

(2018) Harald Hampel et al.   Nature Reviews Neurology

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

(2017) Harutsugu Tatebe et al.   Molecular Neurodegeneration

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

(2016) Sebastian Palmqvist et al.   BRAIN

Developing novel blood-based biomarkers for Alzheimer's disease

(2013) Heather M. Snyder et al.   Alzheimers & Dementia

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease

(2013) Gaël Chételat et al.   NeuroImage-Clinical

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

(2010) C. R. Jack et al.   BRAIN